Cambridge Investment Research Advisors
KRTX

Cambridge Investment Research Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,930
Closed -$419K – 3287
2023
Q2 		$419K Sell
1,930
-70
-4% -$15K ﹤0.01% 2260
2023
Q1 		$363K Sell
2,000
-16
-0.8% -$3.06K ﹤0.01% 2320
2022
Q4 		$396K Sell
2,016
-40
-2% -$8.58K ﹤0.01% 2212
2022
Q3 		$462K Sell
2,056
-4,367
-68% -$884K ﹤0.01% 1998
2022
Q2 		$813K Buy
6,423
+4,251
+196% +$489K ﹤0.01% 1618
2022
Q1 		$275K Buy
2,172
+105
+5% +$11.8K ﹤0.01% 2612
2021
Q4 		$271K Hold
2,067
– – ﹤0.01% 2627
2021
Q3 		$253K Buy
2,067
+15
+0.7% +$1.73K ﹤0.01% 2616
2021
Q2 		$234K Buy
2,052
+64
+3% +$7.48K ﹤0.01% 2684
2021
Q1 		$239K Sell
1,988
-50
-2% -$5.66K ﹤0.01% 2465
2020
Q4 		$207K Buy
+2,038
New +$189K ﹤0.01% 2453

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Cambridge Investment Research Advisors's KRTX Position: Q3 2023 in Review

Cambridge Investment Research Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,930 shares — an estimated $419K sold.

Cambridge Investment Research Advisors first reported a position in KRTX in Q4 2020 and held it in 11 quarters. The position peaked at $813K in Q2 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Cambridge Investment Research Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,930 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $419K.
  • Cambridge Investment Research Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Cambridge Investment Research Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $813K in Q2 2022.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.